Foghorn Therapeutics (FHTX) TD Cowen 46th Annual Health Care Conference summary

Strategic partnerships and pipeline overview

• Maintains a 50/50 partnership with Eli Lilly on the SMARCA2 program, with additional targets under Lilly's rights.

• Proprietary pipeline includes selective CBP, EP300, and ARID1B degrader programs, with IND-enabling studies for CBP and EP300 expected later this year.

• An I&I program targeting a novel mechanism is projected for IND in 2027, pending ongoing validation.

• Recent $50 million direct offering extends financial runway by approximately two quarters at current burn rate.

Clinical progress and trial updates

• SMARCA2 program is in dose escalation, with no maximum tolerated dose reached; backfilling cohorts are ongoing, especially in non-small cell lung cancer with SMARCA4 mutations.

• Enrollment is robust across multiple international sites, supporting seamless transition to dose expansion.

• Decision on dose expansion is anticipated around mid-year, depending on ongoing phase 1 results.

• Safety and tolerability have been favorable so far, with no clinical activity disclosed yet.

Scientific and preclinical highlights

• CBP degrader FHT-171 shows promising preclinical efficacy in ER+ breast cancer models and favorable safety profile compared to dual bromodomain inhibitors.

• EP300 degrader demonstrates activity across hematological malignancies, including multiple myeloma, with minimal impact on blood cell counts.

• ARID1B degrader program has achieved over 80% degradation in preclinical models, aiming for in vivo proof of concept by 2026.

• Long-acting injectable formulations are being developed for VHL-based degraders to enable weekly dosing.